fig1
![The change of paradigm in the treatment of HER2-positive breast cancer with the development of new generation antibody-drug conjugates](https://image.oaes.cc/b4d62d48-f20a-41a4-9340-9e2cc7d111d8/5386.fig.1.jpg)
Figure 1. General structure of an antibody drug conjugate. The antibody drug conjugate contains three key components: antibody, linker, and payload.
Figure 1. General structure of an antibody drug conjugate. The antibody drug conjugate contains three key components: antibody, linker, and payload.
All published articles will preserved here permanently:
https://www.portico.org/publishers/oae/